The controversial role of placental growth factor in tumor growth

Cancer Letters

Volumn 307, Issue 1, 2011, Pages 1-5

  Ribatti, Domenico ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

Angiogenesis; Antiangiogenesis; Placental growth factor; Tumor growth; Vascular endothelial growth factor

Indexed keywords

PLACENTAL GROWTH FACTOR; VASCULOTROPIN;

CARCINOGENESIS; CROSS REACTION; DOWN REGULATION; GENE OVEREXPRESSION; HUMAN; IMMUNOREACTIVITY; LYMPHANGIOGENESIS; MYELOID PROGENITOR CELL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VASCULARIZATION; UPREGULATION;

EID: 79957453885     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.02.043     Document Type: Review

References (70)

1. Maglione D., Guerriero V., Viglietto G., Delli-Bovi P., Persico M.G. Isolation of human placenta cDNA coding for a protein related to the vascular permeability factor. Proc. Natl. Acad. Sci. USA 1991, 88:9267-9271.
2. Iyer S., Leonidas D.D., Swaminathan G.J., Maglione D., Battisti M., Tucci M., Persico M.G., Acharya K.R. The crystal structure of human placental growth factor-1 (PlGF), an angiogenic protein at 2 Å resolution. J. Biol. Chem. 2001, 276:12153-12161.
3. Maglione D., Guerriero V., Viglietto G., Ferraro M.G., Aprelikova O., Alitalo K., Del Vecchio S., Lei K.J., Chou J.Y., Persico M.G. Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14. Oncogene 1993, 8:925-931.
4. Cao Y., Ji W.R., Qi P., Rosin A., Cao Y. Placenta growth factor: identification and characterization of a novel isoform generated by mRNA alternative splicing. Biochem. Biophys. Res. Commun. 1997, 235:493-498.
5. Yang W., Ahm H., Hinrichs M., Torry R.J., Torry D.S. Evidence of a novel isoform of placenta growth factor (PlGF-4) expressed in human throphoblast and endothelial cells. J. Reprod. Immunol. 2003, 60:53-60.
6. Autiero M., Waltenberger J., Communi D., Kranz A., Moons L., Lambrechts D., Kroll J., Plaisance S., De Mol M., Bono F., Kliche S., Fellbrich G., Ballmer-Hofer K., Maglione D., Mayr-Beyrle U., Dewerchin M., Dombrowski S., Stanimirovic D., Van Hummelen P., Dehio C., Hicklin D.J., Persico G., Herbert J.M., Communi D., Shibuya M., Collen D., Conway E.M., Carmeliet P. Role of PlGF in the intra and intermolecular crosstalk between the VEGF receptors and Flt1 and Flk1. Nat. Med. 2003, 9:936-943.
7. Migdal M., Huppertz B., Tessler S., Comforti A., Shibuya M., Reich R., Baumann H., Neufeld G. Neuropilin-1 is a placenta growth factor-2 receptor. J. Biol. Chem. 1998, 273:22272-22278.
8. Miao H.Q., Soker S., Feiner L., Alonso J.L., Raper J.A., Klagsbrun M. Neuropilin-1 mediates collapsin-1/ semaphorin III inhibition of endothelial cell motility: functional competition of collapsin-1 and vascular endothelial growth factor-165. J. Cell Biol. 1999, 146:233-242.
9. Carmeliet P., Moons L., Luttun A., Vincenti V., Compernolle V., De Mol P., Wu Y., Bono F., Devy L., Beck H., Scholz D., Acker T., Di Palma T., Dewerchin M., Noel A., Stalmans I., Barra A., Blacher S., Vandendriessche T., Ponten A., Eriksson U U., Plate K.H., Foidart J.M., Schaper W., Charnock-Jones D.S., Hicklin D.J., Herbert J.M., Collen D., Persico M.G. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 2001, 7:575-583.
10. Ziche M., Maglione D., Ribatti D., Morbidelli L., Lago C.T., Battisti M., Paoletti I., Barra A., Tucci M., Parise G., Vincenti V., Granger H.J., Viglietto G., Persico M.G. Placenta growth factor-1 is chemotactic, mitogenic and angiogenic. Lab. Invest. 1997, 176:517-531.
11. Yonekura H., Sakurai S., Liu X., Migita H., Wang H., Yamagishi S., Nomura M., Abedin M.J., Unoki H., Yamamoto Y., Yamamoto H. Placenta growth factor and vascular endothelial growth factor B and C expression in microvascular endothelial cells and pericytes. Implication in autocrine and paracrine regulation of angiogenesis. J. Biol. Chem. 1999, 274:35172-35178.
12. Hattori K., Heissig B., Wu Y., Dias S., Tejada R., Ferris B., Hicklin D.J., Zhu Z., Bohlen P., Witte L., Hendrikx J., Hackett N.R., Crystal R.G., Moore M.A., Werb Z., Lyden D., Rafii S. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment. Nat. Med. 2002, 8: 841-849.
13. Selvaraj S.K., Giri R.K., Perelman N., Johnson C., Malik P., Kalra V.K. Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. Blood 2003, 102:1515-1524.
14. Kumazaki K., Nakayama M., Suehara N., Wada Y. Expression of vascular endothelial growth factor, placental growth factor, and their receptors Flt-1 and KDR in human placenta under pathological conditions. Hum. Pathol. 2002, 33:1069-1077.
15. Maes C., Coenegrachts L., Stockmans I., daci E., Luttun A., Petryk A., Gopalakrishnan R., Moermans K., Smets N., Verfaillie C.M., carmeliet P., Bouillon R., Carmeliet G. Placental growth factor mediates mesenchymal cell development, cartilage turnover, and bone remodeling during fracture repair. J. Clin. Invest. 2006, 116:1230-1242.
16. Khurana R., Moons L., Shafi S., Luttun A., Collen D., Martin J.F., Carmeliet P., Zachary I.C. Placental growth factor promotes atherosclerotic intimal thickening and macrophage accumulation. Circulation 2005, 111:2828-2836.
17. Torry R.J., Tomanek R.J., Zheng W., Miller S.J., Labarrere C.A., Torry D.S. Hypoxia increases placenta growth factor expression in human myocardium and cultured neonatal rat cardiomyocytes. J. Heart Lung Transplant. 2009, 28:183-190.
18. Cianfarani F., Zambruno G., Brogelli L., Sera F., Lacal P.M., Pesce M., Capogrossi M.C., Failla C.M., Napolitano M., Odorisio T. Placenta growth factor in diabetic wound healing: altered expression and therapeutic potential. Am. J. Pathol. 2006, 169:1167-1182.
19. Chaballe L., Close P., Semples M., delstanche S., Fanielle J., Mooms L., Carmeliet P., Schoenen J., Chariot A., Franzen R. Involvement of placental growth factor in Wallerian degeneration. Glia 2011, 59:379-396.
20. Cao Y., Chen H., Zhou L., Chiang M.K., Anand-Apte B., Weatherbee J.A., Wang Y., Fang F., Flanagan J.G., Tsang M. Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR. J. Biol. Chem. 1996, 271:3154-3162.
21. Xu L., Cochran D.M., Tong R.T., Winkler F., Kashiwagi S., Jain R.K., Fukumura D. Placenta growth factor overexpression inhibits tumor growth, angiogenesis, and metastasis by depleting vascular endothelial growth factor homodimers in orthotopic mouse models. Cancer Res. 2006, 66:3971-3977.
22. Eriksson A., Cao R., Pawliuk R., Berg S.M., Tsang M., Zhou D., Fleet C., Tristaris K., Dissing S., Leboulch P., Cao Y. Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers. Cancer Cell 2002, 1:99-108.
23. Bjorndahl M., Cao R., Erikksson A., Cao Y. Blockage of VEGF-induced angiogenesis by preventing VEGF secretion. Circ. Res. 2004, 94:1443-1450.
24. Marcellini M., De Luca N., Riccioni T., Ciucci A., Orecchia A., Lacal P.M., Ruffini F., Pesce M., Cianfarani F., Zambruno G., Orlandi A., Failla C.M. Increased melanoma growth and metastasis spreading in mice overexpressing placenta growth factor. Am. J. Pathol. 2006, 169:643-654.
25. Xu L., Jain R.K. Down-regulation of placenta growth factor by promoter hypermethylation in human lung and colon carcinoma. Mol. Cancer Res. 2007, 5:873-880.
26. Gigante B., Morlino G., Gentile M.T., Persico M.G., De Falco S. PlGF -/- eNos -/- mice show defective angiogenesis associated with increased oxidative stress in response to tissue ischemia. FASEB J. 2006, 20:E70-E79.
27. Schomber T., Kopfstein L., Djonov V., Albrecht I., Baeriswyl V., Strittmatter K., Christofori G. Placental growth factor-1 attenuates vascular endothelial growth factor-A-dependent tumor angiogenesis during β cell carcinogenesis. Cancer Res. 2007, 67:10840-10848.
28. Hedlund E.M., Hosaka K., Zhomg Z., Cao R., Cao Y. Malignant cell-derived PlGF promotes normalization and remodeling of the tumor vasculature. Proc. Natl. Acad. Sci. USA 2010, 106:17505-17510.
29. Takahashi A., Sasaki H., Kim S.J., Tobisu K., Kakizoe T., Tsukamoto T., Kumamoto Y., Sugimura T., Terada M. Markedly increased amount of messenger RNAs for vascular endothelial growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res. 1994, 54:4233-4237.
30. Viglietto G., Maglione D., Rambaldi M., Cerutti J., Romano A., Trapasso F., Fedele M., Ippolito P., Chiappetta G., Botti G., Fusco A., Persico M.G. Upregulation of Vascular endothelial growth factor (VEGF) and downregulation of Placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 1995, 11:1569-1579.
31. Viglietto G., Romano A., Maglione D., Rambaldi M., Paoletti I., Lago C.T., Califano D., Monaco C., Mineo A., Santelli G., Manzo G., Botti G., Chiappetta G., Persico M.G. Neovascularization in human germ cell tumors correlates with a marked increase in the expression of the vascular endothelial growth factor but not the placenta growth factor. Oncogene 1996, 13:577-587.
32. Zhang L., Chen J., Ke Y., Mansel R.E., Jiang W.G. Expression of Placenta growth factor (PlGF) in non small cell lung cancer (NSCLC) and the clinical and prognostic significance. World J. Surg. Oncol. 2005, 3:68.
33. Wei S.C., Tsao P.N., Yu S.C., Shun C.T., Tsai-Wu J.J., Wu C.H., Su Y.N., Hsieh F.J., Wong J.M. Placenta growth factor expression is correlated with survival of patients with colorectal cancer. Gut 2005, 54:666-672.
34. Chen C.N., Hsieh F.J., Cheng Y.M., Cheng W.F., Su Y.N., Chang K.J., Lee P.H. The significance of placenta growth factor in angiogenesis and clinical outcome of human gastric cancer. Cancer Lett. 2004, 213:73-82.
35. Parr C., Watkins G., Boulton M., Cai J., Jiang W.G. Placental growth factor is over-expressed and has prognostic value in human breast cancer. Eur. J. Cancer 2005, 41:2819-2827.
36. Ho M.C., Chen C.N., Lee H., Hsieh F.J., Shun C.T., Chang C.L., Lai Y.T., Lee P.H. Placenta growth factor not vascular endothelial growth factor A or C can predict the early recurrence after radical resection of hepatocellular carcinoma. Cancer Lett. 2007, 250:237-249.
37. Matsumoto K., Suzuki K., Kolke H., Okamura K., Tsuchiya K., Uchida T., Takezawa Y., Kobayashi M., Yamanaka H. Prognostic significance of plasma placental growth factor levels in renal cell cancer: an association with clinical characteristics and vascular endothelial growth factor levels. Anticancer Res. 2003, 23:4953-4958.
38. Nomura M., Yamagishi S., Harada S., Yamashima T., Yamashita J., Yamamoto H. Placenta growth factor (PlGF) mRNA expression in brain tumors. J. Neurooncol. 1998, 40:123-130.
39. Willett C.G., Boucher Y., Duda D.G., di Tomaso E., Munn L.L., Tong R.T., Kozin S.V., Petit L., Jain R.K., Chung D.C., Sahani D.V., Kalva S.P., Cohen K.S., Scadden D.T., Fischman A.J., Clark J.W., Ryan D.P., Zhu A.X., Blaszkowsky L.S., Shellito P.C., Mino-Kenudson M., Lauwers G.Y. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in renal cancer patients. J. Clin. Oncol. 2005, 23:8136-8139.
40. Rini B.I., Michaelson M.D., Rosenberg J.E., Bukowski R.M., Sosman J.A., Stadler W.M., Hutson T.E., Margolin K., Harmon C.S., DePrimo S.E., Kim S.T., Chen I., George D.J. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J. Clin. Oncol. 2008, 26:3743-3748.
41. Batchelor T.T., Sorensen A.G., di Tomaso E., Zhang W.T., Duda D.G., Cohen K.S., Kozak K.R., Cahill D.P., Chen P.J., Zhu M., Ancukiewicz M., Mrugala M.M., Plotkin S., Drappatz J., Louis D.N., Ivy P., Scadden D.T., Benner T., Loeffler J.S., Wen P.Y., Jain R.K. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11:83-95.
42. Sowter H.M., Corps A.N., Evans A.L., Clark D.E., Charnock-Jones D.S., Smith S.K. Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors. Lab. Invest. 1997, 77:607-614.
43. Nishi J., Minamino T., Miyauchi H H., Nojima A A., Tateno K K., Okada S S., Orimo M., Moriya J J., Fong GH G.H., Sunagawa K K., Shibuya M., Komuro I. Vascular endothelial growth factor receptor-1 regulates postnatal angiogenesis through inhibition of the excessive activation of Akt. Circ. Res. 2008, 103:261-268.
44. Tchaikovski V V., Fellbrich G G., Waltenberger J. The molecular basis of VEGFR-1 signal transduction pathways in primary human monocytes. Arterioscler. Thromb. Vasc. Biol. 2008, 28:322-328.
45. Murakami M., Zheng Y., Hirashima M., Suda T., Morita Y., Oechara J., Ema H., Fong G.H., Shibuya M. VEGFR-1 tyrosine kinase signaling promotes lymphangiogenesis as well as angiogenesis indirectly via macrophage recruitment. Arterioscler. Thromb. Vasc. Biol. 2008, 28:658-664.
46. Hiratsuka S., Maru Y., Okada A., Seiki M., Noda T., Shibuya M. Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res. 2001, 61:1207-1213.
47. Amaoka N., Saio M., Nonaka K., Imai H., Tomita H., Sakashita F., Takahashi T., Sugiyama Y., Takami T., Adachi Y. Expression of vascular endothelial growth factor receptors is closely related to the histologic grade of hepatocellular carcinoma. Oncol. Rep. 2006, 16:3-10.
48. Andre T., Kotelevets L., Vaillant J.C., Coudray A.M., Weber L., Prévot S., Parc R., Gespach C., Chastre E. Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa. Int. J. Cancer 2000, 86:174-181.
49. Donnem T., Al-Saad S., Al-Shibli K., Delghandi M.P., Persson M., Nilsen M.N., Busund L.T., Bremnes R.M. Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer. Clin. Cancer Res. 2007, 13:6649-6657.
50. Ghanem M.A., van Steenbrugge G.J., Sudaryo M.K., Mathoera R.B., Nijman J.M., van der Kwast T.H. Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FLT-1) in nephroblastoma. J. Clin. Pathol. 2003, 56:107-113.
51. Hahn D., Simak R., Steiner G.E., Handisurya A., Susani M., Marberger M. Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues. J. Urol. 2000, 164:506-510.
52. Plate K.H., Breier G., Weich H.A., Mennel HD H.D., Risau W. Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int. J. Cancer 1994, 59:520-529.
53. Schmidt M., Voelker H.U., Kapp M., Dietl J., Kammerer U. Expression of VEGFR-1 (Flt-1) in breast cancer is associated with VEGF expression and with node-negative tumor stage. Anticancer Res. 2008, 28:1719-1724.
54. Takanami I., Tanaka F., Hashizume T., Kodaira S. Vascular endothelial growth factor and its receptors correlate with angiogenesis and survival in pulmonary adenocarcinoma. Anticancer Res. 1997, 17:2811-2814.
55. Fragoso R., Igreja C., Clode N., Henriques A., Appleton C., Zhu Z., Wu Y., Dias S. VEGF signaling of hematopietic precursors restricts B-lymphoid commitment in vitro and in vivo. Exp. Hematol. 2008, 36:1329-1336.
56. Mylona E., Alexandrou P., Giannopolou I., Liapis G G., Sofia M., Keramopoulos A., Nakopoulou L. The prognostic value of vascular endothelial growth factors (VEGFs)-A and -B and their receptor VEGFR-1 in invasive breast carcinoma. Gynecol. Oncol. 2007, 104:557-563.
57. Seto T., Higashiyama M., Funai H., Imamura F., Uematsu K., Seki N., Eguchi K., Yamanaka T., Ichinose Y. Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non small-cell lung cancer. Lung. Cancer 2006, 53:91-96.
58. Luttun A., Tjwa M., Moons L., Wu Y., Angelillo-Scherrer A., Liao F., Nagy J.A., Hooper A., Prille J., De Klerck B., Compernolle V., Daci E., Bohlen P., Dewerchin M., Herbert J.M., Fava R., Mattys P., Carmeliet G., Collen D., Dvorak H.F., Hicklin D.J., Carmeliet P. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat. Med. 2002, 8:81-840.
59. Fisher C., Jonckx B., Mazzone M., Zacchigna S., Loges S., Pattarini L., Chorianopoulos E., Liesenborghs L., Koch M., De Mol M., Autiero M., Wyns S., Plaisance S., Moons L., van Rooijen N., Giacca M., Stassen J.M., Dewerchin M., Collen D., Carmeliet P. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007, 131:463-475.
60. Cursiefen C., Chen L., Borges L.P., Jackson D., Cao J., Radziejewski C., D'Amore P.A., Dana M.R., Wiegand S.J., Streilein J.W. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J. Clin. Invest. 2004, 113:1040-1050.
61. Schoppmann S.F., Birner P., Stöckl J., Kalt R., Ullrich R., Caucig C., Kriehuber E., Nagy K., Alitalo K., Kerjaschki D. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am. J. Pathos. 2002, 161:947-956.
62. Fisher C., Mazzone M., Jonckx B., Carmeliet P. FLT1 and its ligands VEGFB and PlGF: drug targets for antiangiogenic therapy?. Nat. Rev. Cancer 2008, 12:942-956.
63. Taylor A.P., Goldenberg D.M. Role of placenta growth factor in malignancy and evidence that an antagonistic PlGF/Flt-1 peptide inhibits the growth and metastasis of human breast cancer xenografts. Mol. Cancer Ther. 2007, 6:524-531.
64. Dawson M.R., Duda D.G., Chae S.S., Fukumura D., Jain R.K. VEGFR1 activity modulates myeloid cell infiltration in growing lung metastases but is not required for spontaneous metastasis formation. PLoSONE 2009, 4:e6525.
65. Bais C., Wu X., Yao J., Yang S., Crawford Y., McCutcheon K., Tan C., Koluman G., Vernes J.M., Eastham-Anderson J., Haughney P., Kowanetz M., Hagenbeek T., Kasman I., Reslan H.B., Ross J., Van Bruggen N., Carano R.A.D., Meng Y.J.G., Hongo J.A., Stepahn J.P., Shibuya M., Ferrara N. PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell 2010, 141:166-177.
66. Van De Viere S., Stalmans I., Heindryckx F., Oura H., Tijeras-Raballand A., Schmidt T., Loges S., Albrecht I., Jonckx B., Vinckier S., Van Steenkiste C., Tugues S., Rolny C., De Mol M., Dettori D., Hainaud P., Coenegrachts L., Contreres J.O., Van Bergen T., Cuervo H., Xiao W.H., Le Henaff C., Buysschaert I., Kharabi Masouleh B., Geerts A., Schomber T., Bonnin P., Lambert V., Haustraete J., Zacchigna S., Rakic J.M., Jiménez W., Noël A., Giacca M., Colle I., Foidart J.M., Tobelem G., Morales-Ruiz M., Vilar J., Maxwell P., Vinores S.A., Carmeliet G., Dewerchin M., Claesson-Welsh L., Dupuy E., Van Vlierberghe H., Christofori G., Mazzone M., Detmar M., Collen D., Carmeliet P. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer an eye disease. Cell 2010, 141:178-190.
67. Bagley R.G., Kurtzberg L., Weber W., Nguyen T.H., Roth S., Krumbholz R., Yao M., Richards B., Zhang M., Pechan P., Schmid S., Scaria A., Kaplan J., Teicher B.A. SFLT01: a novel fusion protein with anti-angiogenic activity. Mol. Cancer Ther. 2011, 10:404-415.
68. Rolny C., Mazzone M., Tugues S., Laoui D., Johansson I., Coulon C., Squadrito M.L., Segura I., Li X., Knevels E., Costa S., Vinckier S., Dresselaer T., Akerud P., De Mol M., Salomaki H., Phillipson M., Wyns S., Larsson E., Buysschaert I., Botling J., Himmelreich U., Van Ginderachter J.A., De Palma M., Dewerchin M., Claesson-Welsh L., Cameliet P. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 2011, 19:31-44.
69. Verhel H.M., Pinedo H.M. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat. Rev. Cancer 2007, 7:475-485.
70. Force T., Krause D.S., Van Etten R.A. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat. Rev. Cancer 2007, 7:332-344.